Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Treatment of thromboangiitis obliterans ( B uerger's disease) with high‐potency vasodilators

Treatment of thromboangiitis obliterans ( B uerger's disease) with high‐potency vasodilators Thromboangiitis obliterans (TAO) or Buerger's disease is a vascular inflammatory thrombotic occlusive and segmental disease affecting distal small and medium‐sized arteries of the limbs. Tobacco is the main trigger factor and avoiding it is the main treatment. Frequently, it is necessary to use high‐potency vasodilators, such as iloprost, bosentan, sildenafil, or alprostadil, to relieve symptoms and reduce the risk of amputation. Iloprost is the only one that has been shown to be effective in randomized clinical trials. We report the third case of TAO treated with sildenafil and a new case treated with bosentan. This condition can be diagnosed and treated by a dermatologist. We would like to highlight the excellent clinical response despite the fact that patients continued to smoke. This finding may have important therapeutic implications because early treatment may prevent amputation and can be effective even during the process of giving up smoking. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Dermatologic Therapy Wiley

Treatment of thromboangiitis obliterans ( B uerger's disease) with high‐potency vasodilators

Download PDF
5 pages

Loading next page...
 
/lp/wiley/treatment-of-thromboangiitis-obliterans-b-uerger-s-disease-with-high-wN0LAud39M

References (22)

Publisher
Wiley
Copyright
© 2015 Wiley Periodicals, Inc.
ISSN
1396-0296
eISSN
1529-8019
DOI
10.1111/dth.12207
pmid
25649782
Publisher site
See Article on Publisher Site

Abstract

Thromboangiitis obliterans (TAO) or Buerger's disease is a vascular inflammatory thrombotic occlusive and segmental disease affecting distal small and medium‐sized arteries of the limbs. Tobacco is the main trigger factor and avoiding it is the main treatment. Frequently, it is necessary to use high‐potency vasodilators, such as iloprost, bosentan, sildenafil, or alprostadil, to relieve symptoms and reduce the risk of amputation. Iloprost is the only one that has been shown to be effective in randomized clinical trials. We report the third case of TAO treated with sildenafil and a new case treated with bosentan. This condition can be diagnosed and treated by a dermatologist. We would like to highlight the excellent clinical response despite the fact that patients continued to smoke. This finding may have important therapeutic implications because early treatment may prevent amputation and can be effective even during the process of giving up smoking.

Journal

Dermatologic Therapy – Wiley

Published: May 1, 2015

There are no references for this article.